- Home
- GTBP vs QNRX Comparison
GTBP vs QNRX Comparison
Compare GTBP & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTBP | QNRX |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 14.5M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GTBP | QNRX |
|---|---|---|
| Price | $0.36 | $6.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 507.2K | 119.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $5.47 |
| 52 Week High | $3.73 | $41.80 |
Technical Indicators
Market Signals| Indicator | GTBP | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 37.66 |
| Support Level | $0.35 | $5.47 |
| Resistance Level | $0.46 | $6.98 |
| Average True Range (ATR) | 0.03 | 0.51 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 7.96 | 19.86 |
Price Performance
Historical ComparisonAbout GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.